Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science

View original at finance.yahoo.com
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through open science, a new public-…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Abcam serves 750,000 researchers in over 130 countries to help them reach results faster in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders

    80% confidence
  • LIGAND-AI aims to change drug discovery by combining advanced laboratory technologies with computational methods to create a seamless pipeline from experiment to prediction, generating billions of data points

    80% confidence
  • The project brings together scientists and companies from across disciplines within an open science ecosystem, with diverse scientific communities coalescing around a common vision to generate and share valuable chemical data openly with the world

    80% confidence
  • LIGAND-AI represents the next frontier in drug discovery, combining cutting-edge AI with large-scale experimental science to build predictive models that will unlock thousands of new targets

    80% confidence
  • The project represents a major step toward the mission of Target 2035 to discover chemical modulators for every human protein by the year 2035

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com